Nontuberculous Mycobacteria Market Size was valued at USD 8.9 Billion in 2022. The Nontuberculous Mycobacteria market industry is projected to grow from USD 9.12 Billion in 2023 to USD 11.114 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 2.50% during the forecast period (2023 - 2032). The increasing frequency of nontuberculous mycobacterial lung disease, particularly among the senior population worldwide, is one of the major market drivers contributing to the industry's rise.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market for nontuberculous mycobacterial is anticipated to rise in the future due to the rising prevalence of infectious disorders. Pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, are the source of infectious diseases. These infections can spread from person to person and produce a wide range of symptoms and health issues. Furthermore, the market for nontuberculous mycobacterial (NTM) may grow as a result of rising rates of infectious diseases, which can include conditions that can result in NTM infections. This is because increased awareness of NTM infections can lead to early detection and more frequent diagnostic testing, more research and development efforts for NTM treatments, and a greater demand for therapies that target NTM pathogens as a result of increased attention to infectious diseases in healthcare. For instance, as of December 2022, the United Nations International Children's Emergency Fund (UNICEF) stated that the most common infectious disease killing over 700,000 children annually—roughly 2,000 children every day—was pneumonia. Consequently, the market for nontuberculous mycobacterial is expanding because to the rising incidence of infectious disorders.
The market for nontuberculous mycobacterial is anticipated to rise in the future due to the increasing frequency of chronic obstructive pulmonary disease (COPD). The long-term and frequently worsening restriction of lung airflow is the hallmark of chronic obstructive pulmonary disease (COPD), a chronic respiratory illness. Patients with COPD who have nontuberculous mycobacterial (NTM) had a higher exacerbation rate and a more marked drop in their forced expiratory volume in one second (FEV1). The immune system may be weakened and lung tissue may be damaged by COPD, which increases the likelihood that NTM bacteria will infect the lungs. For instance, in March 2023, COPD rates started to rise between 2021 and 2022, with male rates rising from 83.2 to 97.6 per 100,000 people and female rates rising from 72.6 to 97.3, per a report released by The Scottish Public Health Observatory (ScotPHO), a public health organization based in Scotland. Therefore, the market for nontuberculous mycobacterial is growing as a result of the increased prevalence of chronic obstructive pulmonary disease (COPD).
Moreover, to maintain their market position, major players in the nontuberculous mycobacterial market implement new treatment approval procedures. For instance, in June 2021, the US-based pharmaceutical company Paratek Pharmaceuticals Inc. was granted permission to broaden the indication for NUZYRA (omadacycline) in the treatment of adult community-acquired bacterial pneumonia (CABP). In order to combat tetracycline resistance, NUZYRA is a modified tetracycline that works against a variety of bacteria, including atypical strains, drug-resistant strains, Gram-positive and Gram-negative bacteria. Furthermore, in July 2022, NUZYRA was given Fast Track designation by the US federal agency Food and Drug Administration to treat nontuberculous mycobacterial (NTM) lung disease caused by MAC (Mycobacterium avium complex). Thus, driving the Nontuberculous Mycobacteria market revenue.
The Nontuberculous Mycobacteria market segmentation, based on class of drugs includes Oral Antibiotics, IV Antibiotics, Anti Nausea, and Nebulized Antibiotics. The oral antibiotics segment dominated the market because mycobacterial infections can be effectively treated with it. The best medication available to treat NTM infections is an oral antibiotics azithromycin, a macrolide antibiotic that has demonstrated effectiveness against a variety of NTM strains. Clinical recommendations frequently advise using oral antibiotics in combination with other medications to treat NTM infections. Therefore, these variables will propel the expansion of the NTM oral antibiotics category.
Figure 1: Nontuberculous Mycobacteria Market, by Class of Drugs, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Nontuberculous Mycobacteria market area will dominate this market because infections with nontuberculous mycobacterium are so common. The existence of large pharmaceutical corporations, rising research efforts for the creation of new pharmaceuticals, and high healthcare costs are all predicted to contribute to the market's expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Nontuberculous Mycobacteria Market Share By Region 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Nontuberculous Mycobacteria market accounts for the second-largest market share. This industry offers a plethora of chances as more individuals prefer short-term, very effective therapies. Spending by healthcare departments will drive market expansion. The European Medicines Agency is now marketing ARIKACE, an inhalation medication used to treat nontuberculous mycobacterium, as an orphan drug. Further, the German Nontuberculous Mycobacteria market held the largest market share, and the UK Nontuberculous Mycobacteria market was the fastest growing market in the European region
The Asia-Pacific Nontuberculous Mycobacteria Market is expected to grow at the fastest CAGR from 2023 to 2032. The rising prevalence of NTM infections in Asia Pacific, particularly in individuals with compromised immune systems or underlying respiratory conditions, is a significant contributing cause. This area has a sophisticated healthcare infrastructure and a robust pharmaceutical sector in addition to cutting-edge diagnostic capabilities. Moreover, China’s Nontuberculous Mycobacteria market held the largest market share, and the Indian Nontuberculous Mycobacteria market was the fastest growing market in the Asia-Pacific region.
Nontuberculous Mycobacteria Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Nontuberculous Mycobacteria market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Nontuberculous Mycobacteria industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Nontuberculous Mycobacteria industry to benefit clients and increase the market sector. In recent years, the Nontuberculous Mycobacteria industry has offered some of the most significant advantages to medicine. Major players in the Nontuberculous Mycobacteria market are attempting to increase market demand by investing in research and development operations includes Insmed, Paratek Pharmaceuticals Inc, RedHill Biopharma Ltd, Janssen, Novartis AG, RevImmune, and Nobelpharma Co Ltd.
RedHill Biopharma Ltd (RedHill) is a specialized biopharmaceutical business that creates and markets treatments for cancer and gastrointestinal (GI) disorders. The commercial product portfolio of the company include branded prescription medications, such as a combination of omeprazole, amoxicillin, and rifabutin; naloxegol; and rifamycin. For the treatment of Crohn's disease, non-tuberculous mycobacterial infections (NTM) infections, irritable bowel syndrome with diarrhea (IBS-D), gastroenteritis, bowel cleanser, gastritis, cancer, and novel coronavirus disease (COVID-19), RedHill is researching its pipeline candidates.
A multinational biopharmaceutical business called Insmed is dedicated to improving the lives of people suffering from severe and uncommon illnesses. In addition to aiming to comprehend and improve the full patient experience—from diagnosis and treatment to day-to-day living—the company is committed to creating and introducing medicines that truly improve the lives of its patients. It is a quickly expanding firm with locations throughout seven countries, and its headquarters are in Bridgewater, NJ.
Key Companies in the Nontuberculous Mycobacteria market include
Nontuberculous Mycobacteria Industry Developments
January 2022: Gaelan Medical Trade LLC and RedHill Biopharma Ltd., a specialist biopharmaceutical business, have partnered to sell the medication Talicia (omeprazole magnesium, amoxicillin, and rifabutin) in the United Arab Emirates (UAE).
February 2021: BioTelemetry, Inc., a top supplier of remote monitoring and diagnostic services, has been acquired by Koninklijke Philips N.V.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 8.9 Billion |
| Market Size 2023 | USD 9.12 Billion |
| Market Size 2032 | USD 11.114 Billion |
| Compound Annual Growth Rate (CAGR) | 2.50% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Class of Drugs, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Insmed, Paratek Pharmaceuticals Inc, RedHill Biopharma Ltd, Janssen, Novartis AG, RevImmune, and Nobelpharma Co Ltd. |
| Key Market Opportunities | Acceptance Of Approvals For Innovative Treatments |
| Key Market Dynamics | Increasing Infectious Illness Rates Rising Incidence of COPD (Chronic Obstructive Pulmonary Disease) |
Frequently Asked Questions (FAQ) :
The Nontuberculous Mycobacteria market size was valued at USD 8.9 Billion in 2022.
The market is projected to grow at a CAGR of 2.50% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Insmed, Paratek Pharmaceuticals Inc, RedHill Biopharma Ltd, Janssen, Novartis AG, RevImmune, and Nobelpharma Co Ltd.
The oral antibiotics category dominated the market in 2022.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
